7.49
前日終値:
$7.42
開ける:
$7.47
24時間の取引高:
240.10K
Relative Volume:
0.59
時価総額:
$193.26M
収益:
$45.07M
当期純損益:
$-44.49M
株価収益率:
-2.0156
EPS:
-3.716
ネットキャッシュフロー:
$-54.23M
1週間 パフォーマンス:
+7.15%
1か月 パフォーマンス:
-19.03%
6か月 パフォーマンス:
+97.11%
1年 パフォーマンス:
+63.89%
Precision Biosciences Inc Stock (DTIL) Company Profile
名前
Precision Biosciences Inc
セクター
電話
919-314-5512
住所
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
DTIL
Precision Biosciences Inc
|
7.49 | 187.07M | 45.07M | -44.49M | -54.23M | -3.716 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 開始されました | Guggenheim | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-06-09 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 再開されました | BTIG Research | Buy |
| 2020-04-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-05 | 開始されました | Stifel | Buy |
| 2020-02-25 | 開始されました | William Blair | Outperform |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-22 | 開始されました | Barclays | Overweight |
| 2019-04-22 | 開始されました | Goldman | Buy |
| 2019-04-22 | 開始されました | JP Morgan | Overweight |
| 2019-04-22 | 開始されました | Jefferies | Buy |
すべてを表示
Precision Biosciences Inc (DTIL) 最新ニュース
Precision BioSciences Inc (DTIL) Valuation: PE, PB & Fair Value Analysis - TradingKey
DTIL|Precision BioSciences Inc|Price:7.240|Chg%:-0.050 - TradingKey
Precision BioSciences Inc (DTIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precision BioSciences announces leadership changes - Investing.com India
Precision BioSciences (DTIL) Announces Leadership Restructuring for Clinical Development - GuruFocus
Precision BioSciences Inc (DTIL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Precision BioSciences Inc (DTIL) Income Statement - TradingKey
Precision BioSciences Announces Executive Leadership Changes to Advance Gene Editing Programs - Minichart
Precision Biosciences, Inc. Announces Chief Financial Officer Changes, Effective August 1, 2026 - marketscreener.com
Precision BioSciences Announces Key Executive Leadership Changes - TipRanks
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precision BioSciences (DTIL) Announces Leadership Changes - GuruFocus
Precision BioSciences appoints Alex Kelly COO; Naresh Tanna named CFO - TradingView
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones - Business Wire
Precision BioSciences Inc (DTIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precision BioSciences Inc (DTIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lynx1 Capital Management LP Acquires Additional Shares in Precis - GuruFocus
Precision BioSciences Inc (DTIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precision BioSciences (DTIL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline - dars.gov.et
Precision BioSciences (DTIL) Rallies 3.5% as Biotech Stock Tests Key Resistance LevelCovered Call Trade - dars.gov.et
Lynx1 Capital discloses 5.4% Precision BioSciences (DTIL) ownership in Schedule 13G - Stock Titan
Trading the Move, Not the Narrative: (DTIL) Edition - Stock Traders Daily
Precision BioSciences (DTIL) Proxy filing Summary - Quartr
Precision BioSciences announces grant of inducement awards - TipRanks
Precision BioSciences Grants Stock Units to New Employees Amid G - GuruFocus
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 - BioSpace
Precision BioSciences (DTIL) Grants Inducement Awards to New Hir - GuruFocus
Precision BioSciences (DTIL) Slips 4.4% as Stock Tests Key Support LevelsPercent Above MA - dars.gov.et
Precision BioSciences, Inc. Actuals & Estimates (TRADEGATE:PBS0) - TradingView
DTIL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength? - Yahoo Finance
Enterprise value to revenue forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences Updates Investors with Latest Corporate Deck in July 2026 SEC 8-K Filing - Minichart
Precision BioSciences Advances Gene-Editing Programs in Hepatitis B - TipRanks
Precision BioSciences (NASDAQ: DTIL) shares HBV data, DMD trial timeline - Stock Titan
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Index - marketscreener.com
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Value Benchmark - marketscreener.com
Precision BioSciences added to Russell 2000 index By Investing.com - Investing.com Nigeria
Precision BioSciences added to Russell 2000 index - Investing.com
Precision BioSciences (DTIL) Joins Russell 2000 Index, Highlighting Growth Potential - GuruFocus
Index Expanding Market Visibility with Institutional Investors - Business Wire
Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 2000 Dynamic Index - marketscreener.com
Precision BioSciences, Inc. Actuals & Estimates (DUS:PBS0) - TradingView
Price to sales forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Price to earnings forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences, Inc. Actuals & Estimates (NASDAQ:DTIL) - TradingView
Enterprise value to EBIT forward of Precision BioSciences, Inc. – LS:A400AS - TradingView
Enterprise value to revenue forward of Precision BioSciences, Inc. – LS:A400AS - TradingView
DTIL Forecast — Price Target — Prediction for 2027 - TradingView
Precision Biosciences Inc (DTIL) 財務データ
収益
当期純利益
現金流量
EPS
Precision Biosciences Inc (DTIL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
大文字化:
|
ボリューム (24 時間):